Acute Leukemia

March 8, 2009

AML: New Test Helps Predict Relapse, Counter with More Intensive Therapy

Charles H. Weaver, MD
March 8, 2009

Recurrent AML: Antibody-Targeted Therapy, Gemtuzumab Ozogamicn, under FDA Review

Charles H. Weaver, MD
March 8, 2009

Gemtuzumab Ozogamicin A Safe & Effective Option for Patients with Relapsed AML

Charles H. Weaver, MD
March 8, 2009

E Coli-Asparaginase Superior to Erwinia-Asparaginase for Pediatric ALL

Charles H. Weaver, MD
March 8, 2009

Addition of Thalidomide Not Effective in AML or Myelodysplastic Syndromes

Charles H. Weaver, MD
March 8, 2009

Adolescents Have Improved Survival when Treated on Pediatric Protocols for ALL

Charles H. Weaver, MD
March 8, 2009

Additional Therapy Reduces Recurrences in Acute Myeloid Leukemia

Charles H. Weaver, MD
March 8, 2009

Intensified Induction Therapy May Reduce Relapses in APL

Charles H. Weaver, MD
March 8, 2009

C-Kit Levels Indicative of Response to Chemotherapy in AML

Charles H. Weaver, MD
March 8, 2009

Ceplene™ Improves Survival in Acute Myeloid Leukemia

Charles H. Weaver, MD
March 8, 2009

Cancer-Free Survival Improved with Prolonged Maintenance Chemotherapy in AML

Charles H. Weaver, MD
March 8, 2009

Early Allogeneic Stem Cell Transplant is Best Curative Option for AMegL

Charles H. Weaver, MD